ClinicalTrials.gg
CompletedNCT00394082Updated Nov 25, 2019Results posted

ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

A Phase 2 interventional study of ABI-007 and Bevacizumab in Metastatic Breast Cancer, sponsored by Celgene. Completed at 20 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-25.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jun 2006, registered Oct 2006).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms — 18 open to participants now, 22 under way, 2 of them phase 3. Albumin-Bound Paclitaxel · Breast Neoplasms.

Enrollment
57th of 108
50 · median 60
Started
2006
with 8 others
Phase 2
67 of 108
9 open now
Registered
13th of 108
by date
Lead sponsor
9 of 108
Celgene

Among the 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms, this one is the 57th largest by enrollment, is one of 9 that started in 2006, is one of 67 in phase 2, and was the 13th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

18 of the 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms are open now, in 10 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About Albumin-Bound Paclitaxel

Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of weekly ABI-007 in combination with bevacizumab.

The evaluation of progression-free survival of weekly ABI-007 in combination with bevacizumab for patients with previously untreated advanced/metastatic breast cancer.

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

Keywords

  • Metastatic breast cancer, Abraxane, Bevacizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed adenocarcinoma of the breast.
  • Stage IV disease.
  • (defined as the presence of at least one lesion that can be accurately measured in at least one dimension with longest diameter greater or = 1.0 cm with spiral computed tomography (CT) scan).
  • Patients must not be a candidate for Herceptin therapy (i.e., patients with positive disease (gene amplification by fluorescence in situ hybridization (FISH) or 3 + overexpression by ICH) and patients with unknown HER-2 status are ineligible unless the treating physicians has determined that Herceptin-based therapy would be inappropriate or not indicated).
  • For subjects with prior anthracycline exposure, normal cardiac function including a baseline left ventricle >50% or above institution's lower limit of normal and a normal (ECG) (as assessed by the investigator).
  • At least 2 weeks since radiotherapy, with full recovery. The measurable disease must be completely outside the radiation portal or there must be pathologic proof of progressive disease within the radiation portal.
  • (INR) \< 1.5 and activated partial thromboplastin time within normal limits (APTT WNL).
  • (ECOG) performance status of 0-2.
  • Female > 18 years of age.
  • Patients have the following blood counts at Baseline: (ANC) greater or equal to 1.5 x 10\^9 cells/L; greater or equal 100 x 10\^9 cells/L; (Hgb) greater or equal to 9g/dL.
  • Patients have the following blood chemistry levels at Baseline: (AST or SGOT), alanine aminotransferase (ALT or SGPT) less than or equal 2.5x (ULN) range (less than or equal 5x ULN if patient has known liver ); total greater than or equal to ULN; creatinine greater or equal to 1.5mg/dL.
  • if female of , pregnancy test is negative within 72 hours of first dose of study drug.
  • if fertile, the patient agrees to use an effective method to avoid pregnancy for the duration of the study.
  • has been obtained.

Exclusion criteria

Exclusion Criteria:

  • No prior chemotherapy for or locally recurrent disease is allowed.
  • Prio chemotherapy is allowed, and patients must have recovered from the acute toxicity of such therapies.

    • if a taxane was part of the adjuvant regimen, at least 12 months must have elapsed between the last dose of the taxane and the date of diagnosis of metastatic disease.
    • if a non-taxane-based adjuvant therapy was administered, at least six months must have elapsed between the last dose of the non- taxane-containing chemotherapy and the date of diagnosis of metastatic disease.
  • Concurrent immunotherapy or hormonal therapy.
  • Parenchymal , including .
  • Uncontrolled hypertension (defined as blood pressure of > 150/100 mmHg)
  • Grade 2 or greater congestive heart failure
  • History of coagulopathy, bleeding diathesis, therapeutic anticoagulation other than low dose or chronic ASA greater than or equal to 325 mg per day. Low dose coumadin for anticoagulation of venous access device or low dose molecular weight heparin (LMWH)for deep vein thrombosis prophylaxis or low dose (325 mg or less) ASA prophylaxis are allowed, but are best avoided if the treating physician feels it is safe to do so.
  • Urine protein:creatinine ratio less than or equal to 1.0 at screening.
  • No history of cerebrovascular accident within six months of study entry.
  • Active symptomatic peripheral vascular disease (e.g. aortic aneurysm, claudication) within six months of study entry.
  • Uncontrolled or severe cardiovascular disease including myocardial infarction or unstable angina within six months of study entry.
  • No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal process within six months of study entry.
  • No serious non-healing wound, ulcer, or bone fracture
  • Major surgical procedure, open , or significant traumatic injury within 28 days prior to first dose, or anticipation of need for major surgical procedure during the course of the study. No minor surgical procedure within seven days of study entry. Serious intercurrent medical or psychiatric illness, including serious active infection.
  • History of other within the last 5 years which could affect the diagnosis or assessment of breast cancer.
  • Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study.
  • Pregnant or nursing women.
  • Patients with current sensory neuropathy of > Grade 1 will be excluded.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    ABI-007 plus Bevacizumab

    ABI-007 is administered on days 1, 8 and 15 at 125 mg/m\^2 and bevacizumab is administered on day 1 and 15 at 10 mg/kg of each 28 day cycle. Treatment continues until disease progression or intolerable toxicity. If a patient develops intolerable toxicity to only one of the drugs, the other drug may be continued as single agent therapy in the absence of progression, as long as the treating physician feels this is in the best interests of the patient.

    Drug: ABI-007 · Drug: Bevacizumab

Interventions

  • 125 mg/m\^2 of ABI-007 administered by intravenously (IV) over 30 minutes on days 1, 8 and 15 of each 28 day cycle.

    Also known as: Abraxane®, Nab-paclitaxel

  • Bevacizumab administered once every 2 weeks (10 mg/kg) by IV infusion after ABI-007 has been given. The first dose is one Day 1, cycle 1.

    Also known as: NSC 704865, RhuMAb VEGF, Recombinant Humanized Monoclonal Bevacizumab Antibody

06

What researchers measure

Primary outcomes

  1. Participants With At Least One Treatment-Emergent Adverse Event (TEAE)

    Count of study participants who had at least one treatment-emergent adverse event (TEAE) defined as any adverse event that began or worsened in grade after the start of study drug through 30 days after the last dose of study drug.

    Time frame: up to 25 months

  2. Kaplan-Meier Estimates for Progression-free Survival

    Progression-free survival is defined as the time from first dose of study drug to the start of disease progression or patient death, whichever occurs first. Patients who do not have disease progression or have not died at the end of follow-up were censored at the last known time the patient was progression free. Patients that initiate other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Response Evaluation Criteria in Solid Tumors (RECIST) defines progressive disease (PD) as a \>= 20% increase taking as reference the smallest sum of the longest diameters recorded since the treatment started; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.

    Time frame: up to 39 months

Secondary outcomes

  1. Percentage of Participants With Objective Confirmed Complete or Partial Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST)

    Objective response is complete response (CR) + partial response (PR). RECIST defines overall response of CR as the disappearance of all target and non-target lesions and no appearance of new lesions, confirmed at least 4 weeks after initial documentation. Overall response of PR is defined as \>= 30% decrease from baseline in the sum of the longest diameters of target lesions and no progression of non-target lesions and no appearance of new lesions, confirmed at least 4 weeks after initial documentation. PR is also recorded when all measurable disease has completely disappeared, but a non-measurable component (i.e., ascites) is still present but not progressing and no appearance of new lesions. The objective response is determined by combining the response of target and non-target lesions and the appearance of new lesion(s) or not together.

    Time frame: up to 39 months

  2. Percentage of Participants With Stable Disease for >= 16 Weeks, or Complete or Partial Response According to Response Evaluation Criteria in Solid Tumors (RECIST)

    Disease control is stable disease (SD) for \>=16 weeks + complete response (CR) + partial response (PR). RECIST defines SD as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease and no new lesions. Definitions for CR and PR can be found in outcome #3.

    Time frame: up to 39 months

  3. Kaplan-Meier Estimate for Duration of Response

    Duration of response is defined as progression-free survival in responders, i.e. as the time between the start of a complete response (CR) or partial response (PR) and the start of progressive disease (PD) or patient death from any cause, whichever occurred first. Patients that did not have progression or have not died were censored at the last known time the patient was progression free. Patients that initiate other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Progressive disease is defined in outcome #2. Complete response (CR) and partial response (PR) are defined in outcome #3.

    Time frame: up to 39 months

  4. Kaplan-Meier Estimates for Participant Survival

    Participant survival is the time from the first dose of study drug to patient death from any cause. Patients that did not die were censored at the last known time the patient was alive.

    Time frame: up to 39 months

07

Results

Posted May 22, 2013
Limitations and caveats
Interpretation of results is limited since the cell receptor subtype status of patients is not known.

Participant flow

Participant flow — Overall Study
MilestoneABI-007 Plus Bevacizumab
Started50
At least one response assessment43
Completed24
Not completed26
Withdrew: Unacceptable toxicity15
Withdrew: Adverse event4
Withdrew: Physician decision4
Withdrew: Withdrawal by subject2
Withdrew: Other1

Outcome measures

PrimaryParticipants With At Least One Treatment-Emergent Adverse Event (TEAE)

Count of study participants who had at least one treatment-emergent adverse event (TEAE) defined as any adverse event that began or worsened in grade after the start of study drug through 30 days after the last dose of study drug.

Time frame:
up to 25 months
Reported as:
Number · participants
Participants With At Least One Treatment-Emergent Adverse Event (TEAE)
participantsABI-007 Plus Bevacizumab
Participants With At Least One Treatment-Emergent Adverse Event (TEAE)50
PrimaryKaplan-Meier Estimates for Progression-free Survival

Progression-free survival is defined as the time from first dose of study drug to the start of disease progression or patient death, whichever occurs first. Patients who do not have disease progression or have not died at the end of follow-up were censored at the last known time the patient was progression free. Patients that initiate other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Response Evaluation Criteria in Solid Tumors (RECIST) defines progressive disease (PD) as a \>= 20% increase taking as reference the smallest sum of the longest diameters recorded since the treatment started; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.

Time frame:
up to 39 months
Reported as:
Median · months
Kaplan-Meier Estimates for Progression-free Survival
monthsABI-007 Plus Bevacizumab
Kaplan-Meier Estimates for Progression-free Survival8.0 (5.3 to 10.3)
SecondaryPercentage of Participants With Objective Confirmed Complete or Partial Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST)

Objective response is complete response (CR) + partial response (PR). RECIST defines overall response of CR as the disappearance of all target and non-target lesions and no appearance of new lesions, confirmed at least 4 weeks after initial documentation. Overall response of PR is defined as \>= 30% decrease from baseline in the sum of the longest diameters of target lesions and no progression of non-target lesions and no appearance of new lesions, confirmed at least 4 weeks after initial documentation. PR is also recorded when all measurable disease has completely disappeared, but a non-measurable component (i.e., ascites) is still present but not progressing and no appearance of new lesions. The objective response is determined by combining the response of target and non-target lesions and the appearance of new lesion(s) or not together.

Time frame:
up to 39 months
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Confirmed Complete or Partial Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST)
percentage of participantsABI-007 Plus Bevacizumab
Overall response (CR + PR)30 (17.3 to 42.7)
Complete response (CR)0 (NA to NA)
Partial response (PR)30 (NA to NA)
SecondaryPercentage of Participants With Stable Disease for >= 16 Weeks, or Complete or Partial Response According to Response Evaluation Criteria in Solid Tumors (RECIST)

Disease control is stable disease (SD) for \>=16 weeks + complete response (CR) + partial response (PR). RECIST defines SD as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease and no new lesions. Definitions for CR and PR can be found in outcome #3.

Time frame:
up to 39 months
Reported as:
Number · percentage of participants
Percentage of Participants With Stable Disease for >= 16 Weeks, or Complete or Partial Response According to Response Evaluation Criteria in Solid Tumors (RECIST)
percentage of participantsABI-007 Plus Bevacizumab
CR + PR + SD>=16 weeks50 (36.1 to 63.9)
Complete response (CR)0 (NA to NA)
Partial response (PR)30 (NA to NA)
Stable disease >=16 weeks (SD>=16 weeks)20 (NA to NA)
SecondaryKaplan-Meier Estimate for Duration of Response

Duration of response is defined as progression-free survival in responders, i.e. as the time between the start of a complete response (CR) or partial response (PR) and the start of progressive disease (PD) or patient death from any cause, whichever occurred first. Patients that did not have progression or have not died were censored at the last known time the patient was progression free. Patients that initiate other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Progressive disease is defined in outcome #2. Complete response (CR) and partial response (PR) are defined in outcome #3.

Time frame:
up to 39 months
Reported as:
Median · months
Kaplan-Meier Estimate for Duration of Response
monthsABI-007 Plus Bevacizumab
Kaplan-Meier Estimate for Duration of Response10.3 (9.0 to 20.8)
SecondaryKaplan-Meier Estimates for Participant Survival

Participant survival is the time from the first dose of study drug to patient death from any cause. Patients that did not die were censored at the last known time the patient was alive.

Time frame:
up to 39 months
Reported as:
Median · months
Kaplan-Meier Estimates for Participant Survival
monthsABI-007 Plus Bevacizumab
Kaplan-Meier Estimates for Participant Survival17.1 (13.7 to 23.8)

Adverse events

Collected over up to 25 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABI-007 Plus Bevacizumab—13/50 (26%)50/50 (100%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventABI-007 Plus Bevacizumab
Febrile neutropeniaBlood and lymphatic system disorders3/50
NeutropeniaBlood and lymphatic system disorders1/50
DehydrationMetabolism and nutrition disorders1/50
Electrolyte imbalanceMetabolism and nutrition disorders1/50
HypovolaemiaMetabolism and nutrition disorders1/50
Pneumonitis chemicalInjury, poisoning and procedural complications1/50
Spinal compression fractureInjury, poisoning and procedural complications1/50
HypoxiaRespiratory, thoracic and mediastinal disorders1/50
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/50
PancreatitisGastrointestinal disorders1/50
Most frequent other events
Showing 10 of 74
Most frequent other events
EventABI-007 Plus Bevacizumab
FatigueGeneral disorders35/50
NauseaGastrointestinal disorders34/50
AlopeciaSkin and subcutaneous tissue disorders31/50
EpistaxisRespiratory, thoracic and mediastinal disorders26/50
NeutropeniaBlood and lymphatic system disorders20/50
DiarrhoeaGastrointestinal disorders19/50
HeadacheNervous system disorders18/50
DyspnoeaRespiratory, thoracic and mediastinal disorders17/50
ConstipationGastrointestinal disorders16/50
NeuropathyNervous system disorders15/50

Baseline characteristics

Age, Continuous
Age, Continuous(years)ABI-007 Plus Bevacizumab
Mean57.6 ± 11.03
Sex: Female, Male
Sex: Female, Male(Participants)ABI-007 Plus Bevacizumab
Female50
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)ABI-007 Plus Bevacizumab
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American3
White, Non-Hispanic and Non-Latino40
White, Hispanic or Latino7
Other0
Weight
Weight(kilograms)ABI-007 Plus Bevacizumab
Mean74.52 ± 15.430
Menopausal status
Menopausal status(participants)ABI-007 Plus Bevacizumab
Pre-menopausal7
Post-menopausal43
Eastern Cooperative Oncology Group (ECOG) status
Eastern Cooperative Oncology Group (ECOG) status(participants)ABI-007 Plus Bevacizumab
0 (Fully Active)23
1 (Restrictive but Ambulatory)25
2 (Ambulatory but Unable to Work)2
3 (Limited Self-Care)0
4 (Completely Disabled)0
Time from First Documented Metastasis/Relapse to Study Entry
Time from First Documented Metastasis/Relapse to Study Entry(years)ABI-007 Plus Bevacizumab
Mean1.01 ± 3.123
Dominant Current Site of Metastasis/Relapse
Dominant Current Site of Metastasis/Relapse(participants)ABI-007 Plus Bevacizumab
Visceral49
Non Visceral1
08

Study locations

20 sites
  • Melbourne, Florida 32901, United States
  • Ocoee, Florida 34761, United States
  • Niles, Illinois 60714, United States
  • Terre Haute, Indiana 47802, United States
  • Columbia, Maryland 21044, United States
  • Westminister, Maryland 21157, United States
  • Saint Joseph, Missouri 64507, United States
  • Rochester, New York 14623, United States
  • Bedford, Texas 76022, United States
  • Dallas, Texas 75246, United States
  • El Paso, Texas 79915, United States
  • Odessa, Texas 79761, United States
  • San Antonio, Texas 78229, United States
  • Tyler, Texas 75702, United States
  • Fairfax, Virginia 22031, United States
  • Norfolk, Virginia 23502, United States
  • Salem, Virginia 24153, United States
  • Burien, Washington 98166, United States
  • Edmonds, Washington 98026, United States
  • Vancouver, Washington 98684, United States
09

References and documents

Publications

  • Danso M, et al. Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer. Presented at 2008 ASCO Annual Meeting, May 30-June 3, 2008, Chicago, IL. Abstract No. 1075.
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2006 to primary completion in Sep 2009, 39 months.

Results were first posted in May 2013, 3 years 8 months after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 39 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2006
First posted
Oct 31, 2006
StartActual
Jun 1, 2006
Primary completionActual
Sep 1, 2009
CompletionActual
Feb 1, 2011
Results first posted
May 22, 2013
Last update
Nov 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00394082
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Oct 31, 2006
Start date
Jun 1, 2006
Primary completion
Sep 1, 2009
Completion
Feb 1, 2011
Results posted
May 22, 2013
Last update
Nov 25, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albumin-Bound Paclitaxel

Start the discussion